Apyx Medical Corp (BOV.SG)
| Previous close | 1.3300 |
| Open | 1.2800 |
| Bid | 1.3400 x 0 |
| Ask | 1.3900 x 0 |
| Day's range | 1.2800 - 1.2900 |
| 52-week range | 1.1200 - 6.9000 |
| Volume | |
| Avg. volume | 16 |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Apyx Medical Corporation to Release First Quarter of Fiscal Year 2024 Financial Results on May 9, 2024
CLEARWATER, Fla., April 25, 2024--Apyx Medical Corporation (NASDAQ:APYX) (the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today announced that financial results for the first quarter of fiscal year 2024 will be released before the market opens on Thursday, May 9th.
- Business Wire
Apyx Medical Corporation Showcases New Data and Treatment Insights at the Renuvion® Users’ Summit
CLEARWATER, Fla., April 11, 2024--Apyx® Medical Corporation (NASDAQ:APYX) (the "Apyx Medical"; "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, is pleased to announce the Renuvion Users’ Summit is taking place in Las Vegas from April 12-13, 2024.
- Business Wire
Apyx Medical Corporation Reports Fourth Quarter and Full Year 2023 Financial Results; Introduces Full Year 2024 Financial Outlook
CLEARWATER, Fla., March 21, 2024--Apyx Medical Corporation (NASDAQ:APYX) ("Apyx Medical;" the "Company"), the manufacturer of a proprietary helium plasma and radiofrequency technology marketed and sold as Renuvion®, today reported financial results for its fourth quarter and full year ended December 31, 2023, and introduced financial expectations for the full year ending December 31, 2024.
